MODERN-HEALTH
Modern Health, en førende mental sundhedsplatform på det globale arbejdsmarked og Generali Health Solutions GmbH offentliggør i dag et eksklusivt partnerskab. Som udbyder af bevist effektive sundhedsprogrammer er Generali Health Solutions GmbH en del af den internationale Generali Group, som er en af de største globale udbydere af forsikringer og formueforvaltning. Dette partnerskab kommer på et tidspunkt, hvor der er et stigende behov for support af den mentale sundhed på arbejdspladsen. Depression er den førende årsag til uarbejdsdygtighed i verden med 12 milliarder mistede arbejdsdage pga. depression og angst, hvilket giver et anslået årligt tab i produktivitet på USD 1 billion. Partnerskabet gør det nu muligt for arbejdsgivere i mere end 50 lande at investere i mental sundhed for deres medarbejdere, hvilket er et stort skridt fremad i prioriteringen af mental sundhed på global skala.
“Vi er overbeviste om, at global retfærdighed i mental sundhed skal gå længere end adgang til eller appoversættelser – det skal være en integreret del af hvert enkelt aspekt i omsorg for og afspejling af hver person og deres unikke oplevelser,” siger Alyson Watson, grundlægger og adm. direktør for Modern Health. “Vi sætter enkeltpersoner i centrum for deres mentale sundhedsforløb og sikrer, at mental sundhed føles så personlig som den person, den skal hjælpe. Vi er imponerede over Generalis tilsagn til deres kunder og er beærede over at blive partner for at forbedre livet for mennesker over hele verden med ægte global og personlig mental sundhedsomsorg, der giver de bedste resultater for medlemmer, hvad der behov må være, eller hvor de bor.”
Dette samarbejde giver arbejdsgivere mulighed for nemt at få adgang til Modern Healths omfattende globale mentale sundhedsfordele på det globale arbejdsmarked via Generali Health Solutions. Dette omfatter en-til-en-support fra autoriserede terapeuter og certificerede coaches, gruppefællesskabs Circles, de første i branchen Pathways, krisesupport og en omfattende samling digitale ressourcer via selvbetjening til emotionelle, professionelle, sociale, økonomiske og fysiske velfærdsbehov – alt sammen på en platform. Modern Healths innovative og bæredygtige trindopdelte omsorgsmetode giver en solid, beviselig support for hele den globale arbejdsstyrke, der medfører målbare resultater for alle, lige meget hvad de lever med.
"Vores mål er et give vores kunder innovative løsninger, som fremmer sundhed og modstandsdygtighed på arbejdspladsen og således øge medarbejdernes produktivitet," forklarer Dr. Markus Homann, adm. direktør for Generali Health Solutions. “Vi ved, at der er et stigende behov for velfærdssupport på arbejdspladsen og ved at slå os sammen med Modern Health kan vi nemt og uden problemer forbinde vores kunder til det bedste på markedet for globale mental sundhedspleje.”
Gå til Modern Health eller Generali Health Solutions for at få mere at vide.
Om Modern Health
Modern Health er en omfattende global løsning på mental sundhed, som tilbyder medarbejdere adgang til en-til-en-, gruppe- og selvbetjenings digitale ressourcer til deres emotionelle, professionelle, sociale, økonomiske og fysiske velfærdsbehov - alt på én platform. Når en person ønsker proaktivt at håndtere stress eller behandle depression, guider Modern Health disse mennesker til den rigtige hjælp på det rigtige tidspunkt.
Modern Health støttes af investorer som Kleiner Perkins, Founders Fund, John Doerr, Y Combinator og Battery Ventures og skaffede mere end USD 170 millioner på mindre end to år, hvilket gør Modern Health til det hurtigst helt kvindegrundlagte firma i USA til at nå Unicorn-status.
Om Generali Health Solutions
Generali Health Solutions GmbH (GHS) er en del af den internationale Generali Group. Som udbyder af beviseligt effektive sundhedsprogrammer, som kan bruges i virksomheder, forsikringsselskaber og andre institutioner, skaber GHS primært løsninger, som hjælper medarbejdere med at fortsætte med at være produktive og mere tilfredse. Derudover er målet at reducere produktivitetstab og behandlingsomkostninger pga. Sygdom.
For at se dette indhold fra cts.businesswire.com, så skal du give din accept på toppen af denne side.
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20240716732760/da/
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Vonage Network APIs Pave the Way for Freenow by Lyft to Advance Urban Mobility Innovation22.1.2026 08:00:00 CET | Press release
Freenow adopts Vonage APIs to access network capabilities, strengthening fraud prevention through faster, verified connections with drivers for millions of riders Vonage, a part of Ericsson, and Freenow by Lyft, a leading taxi and multi-mobility app in Europe, have expanded their partnership with the launch of Vonage Silent Authentication API for customers based in the U.S. Vonage Network APIs enable Freenow by Lyft to tap into real-time network data and insights, helping prevent fraud through seamless user verification, ensuring reliable, efficient, and secure interactions for its customers and drivers. Network intelligence is becoming a critical layer of defense in the transportation space as fraud threats become more sophisticated and targeted. Enterprises worldwide lost 7.7% of their annual revenue on average due to fraud over the past year, representing an estimated $534 billion in losses.¹ With scam/authorization fraud, synthetic identity fraud, and account takeover as the leadin
Daiichi Sankyo Appoints New Leadership at the Daiichi Sankyo Translational Research Center Europe22.1.2026 07:30:00 CET | Press release
Daiichi Sankyo (TSE:4568) has appointed Veronika Rozehnal, Ph.D., to succeed Jürgen Müller, Ph.D., as the Head of the Translational Research Center Europe. Dr. Jürgen Müller will retire after nearly 30 years of research work at Daiichi Sankyo. Under his leadership, the Translational Research Center Europe, previously called the Tissue and Cell Research Center Munich, has grown from three to 40 researchers since it was founded in 1997 and has become an internationally recognized institution that plays a strategic role in the global innovation process of Daiichi Sankyo. Dr. Veronika Rozehnal joined Daiichi Sankyo in 2009 and has held various positions at the Translational Research Center Europe in addition to spending three years at the Daiichi Sankyo R&D Center in Tokyo. Dr. Rozehnal graduated from Ernst-Moritz-Arndt University of Greifswald, Germany with a Ph.D. degree in Clinical Pharmacology. “Jürgen Müller has made significant scientific contributions that have helped Daiichi Sankyo
Azafaros Announces Key Scientific Oral and Poster Presentations on Nizubaglustat Accepted for WORLDSymposium™ 202622.1.2026 07:00:00 CET | Press release
Five presentations will showcase nizubaglustat’s therapeutic potential in Lysosomal Storage Disorders. Nizubaglustat is currently being tested in two global Phase 3 studies for Niemann-Pick type C disease and GM1/GM2 gangliosidoses which are currently recruiting. Azafaros will host a satellite symposium on nizubaglustat on Day 2 of the symposium discussing the Phase 3 studies. WORLDSymposium™ 2026 takes place from February 2 to 6 in San Diego, California. Azafaros, a company building a portfolio to become a leader in lysosomal storage disorders with the goal of addressing neurological symptoms, today announced that its lead asset, nizubaglustat, will feature in five scientific presentations accepted at the WORLDSymposium™ 2026, the leading global conference on lysosomal diseases, taking place in San Diego, California, USA between February 2-6. The company’s conference activities include: Oral Presentations (including Poster numbers 134 and 29-C) Long-term data from a Phase II study wit
I Squared Announces Launch of Radiant Energy Solutions22.1.2026 07:00:00 CET | Press release
I Squared Capital (“I Squared”), a leading global infrastructure investment manager, announced today the launch of Radiant Energy Solutions (“Radiant”), an investment from I Squared’s Middle East infrastructure strategy, which is focused on targeting transformational, mid-market investments in the region. Reflecting I Squared’s platform-building approach of starting with a core initial investment and scaling over time to build market-leading businesses, Radiant marks the firm’s entry into the Middle East distributed renewables market, providing decarbonization solutions to commercial and industrial customers. The investment for Radiant is the acquisition of FAS Renewables and its 100% owned subsidiary Zahra Energy, a Saudi Arabia–based distributed solar company with a secured and advanced portfolio of over 100MWp of distributed solar projects with established customers and long-term contracted solar power purchase agreements. These include Cenomi Centers, an owner, operator, and develo
IMCAS 2026: Galderma Showcases the Latest Scientific Advances Behind the Industry’s Broadest Injectable Aesthetics Portfolio22.1.2026 07:00:00 CET | Press release
At IMCAS 2026, Galderma will present findings supporting Sculptra’s® regenerative properties and benefits on the body, including improving cellulite appearance, firmness, lift, projection, and contouring following its European Union (EU) Medical Device Regulation (MDR) certification, expanding its use to four body areas1-7 Multiple studies will reinforce the safety and efficacy of Galderma’s hyaluronic acid (HA) treatments range, including post-marketing data on Restylane® Shaype™ in shaping the chin, Restylane Lyft™ in improving jawline definition, Restylane Skinboosters™ in smoothing fine lines and wrinkles in the décolletage and Restylane Volyme™ in correcting hollowing of the temples8-11 New data on the innovative neuromodulator Relfydess™ (RelabotulinumtoxinA) will reinforce its rapid onset as early as Day 1 and sustained efficacy through six months for frown lines and crow’s feet12 As a leader in injectable aesthetic innovation, Galderma will showcase its superior science and edu
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum
